Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma

NCT05849610 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT05849610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05849610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 21, 2023
Completion date
July 31, 2029
Enrollment
30 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk de novo multiple myeloma